The present invention is directed to dosage forms that can be used in therapeuticmethods involving the oral co-administration of a combination of at least twodrugs, one of which impairs gastrointestinal absorption and one of which doesnot. The dosage forms are designed so that the drug impairing absorption is notreleased into the gastrointestinal tract of a patient until after the drugs thatdo not impair absorption have been released and substantially absorbed. Theinvention may be used in treatment of migraine using a combination of triptansand NSAlDs or in the treatment of pain using a combination of NSAIDs and opioidanalgesics.
